

Important Notes: Information mentioned in this document is intended to provide you with a general summary of the ILP Sub-Fund and are subject to change. Please read the Policy (including Policy Illustration, Product Summary and Fund Summary) for the full details of the standard terms and conditions and the exclusions of the insurance product and ILP Sub-Fund.

This Product Highlights Sheet (“PHS”) is an important document.

- It highlights the key terms and risks of the ILP Sub-Fund and complements the Product Summary and Fund Summary.
- It is important to read the Product Summary and the Fund Summary before deciding whether to purchase the ILP Sub-Fund. If you do not have a copy, please contact us to ask for one.
- You should not invest in the ILP Sub-Fund if you do not understand it or are not comfortable with the accompanying risks.
- Unless otherwise defined, capitalised terms in this PHS have been defined in the Fund Summary.

Investment risk rating is used as a guide to determine the ILP Sub-Fund that is suitable to the risk profile as indicated in the Bank’s Risk Profile Questionnaire (RPQ). It is currently only applicable to customers of HSBC Bank (Singapore) Limited (the “Bank”).

Franklin Templeton Investment Funds – Franklin Biotechnology Discovery Fund (the "ILP Sub-Fund")

Product Type	ILP Sub-Fund¹	Launch Date	3 April 2000
Manager	Franklin Templeton International Services S.à r.l.	Custodian	J.P. Morgan Bank Luxembourg S.A.
Capital Guaranteed	No	Dealing Frequency	Each Dealing Date
Name of Guarantor	N.A.	Expense Ratio as at 30 June 2019	Class A SGD: 1.82% Class A USD: 1.82%
ILP Sub-Fund Share Class	Franklin Templeton Investment Funds – Franklin Biotechnology Discovery Fund – A SGD Franklin Templeton Investment Funds – Franklin Biotechnology Discovery Fund – A USD		

ILP SUB-FUND SUITABILITY

<p>WHO IS THE ILP SUB-FUND SUITABLE FOR?</p> <p>The ILP Sub-Fund is only suitable for potential investors who:</p> <ul style="list-style-type: none"> • seek capital appreciation; • seek a growth investment in the technology sector in the biotechnology sector in the US and around the world; and • plan to hold their investment for the medium to long term. <p>The principle may be at risk.</p>	<p><u>Further Information</u> Refer to Section 5 and Section 7 of the Fund Summary for further information on the ILP Sub-Fund.</p>
--	--

KEY FEATURES OF THE ILP SUB-FUND

<p>WHAT ARE YOU INVESTING IN?</p> <p>The ILP Sub-Fund invests 100% into Franklin Templeton Investment Funds–Franklin Biotechnology Discovery Fund (the “Fund”). The Fund is an open-ended collective investment scheme constituted in Luxembourg as a UCITS that aims to provide you with</p>	<p>Refer to Section 2, Section 5 and</p>
--	--

¹The ILP Sub-Fund is not classified as Excluded Investment Product.

capital appreciation by a growth investment in equity securities in the biotechnology sector in the US and around the world.	Section 16 of the Fund Summary for further information on features of the ILP Sub-Fund.
There will be no distribution of dividends by the Fund.	
Investment Strategy	
<ul style="list-style-type: none"> The Fund will invest principally in equity securities of biotechnology companies and discovery research firms of any size located in the US and other countries. It may also invest in debt securities of any type of issuers worldwide. A biotechnology company is one that has at least 50% of its earnings coming from, or at least 50% of its net assets devoted to, biotechnology activities. The Fund will usually invest more in the US than in any other individual country although it may have more than 50% of its net assets in non-US securities. The Fund may invest in derivatives for the purposes of hedging and/or efficient portfolio management. 	Refer to Section 5 of the Fund Summary for the further information on the investment focus and approach of the ILP Sub-Fund.
Parties Involved	
WHO ARE YOU INVESTING WITH?	
<ul style="list-style-type: none"> The investment manager is Franklin Advisers, Inc. The management company is Franklin Templeton International Services S.à r.l. The custodian is J.P. Morgan Bank Luxembourg S.A. 	Refer to Section 3 of the Fund Summary for further information on the roles and responsibilities of these entities and what happens if they become insolvent.
Key Risks	
WHAT ARE THE KEY RISKS OF THIS INVESTMENT?	
The value of the Fund may rise or fall. These risk factors may cause you to lose some or all of your investment.	
Refer to Section 7.1 of the Fund Summary for further information on risks of the ILP Sub-Fund.	
Market and Credit Risks	
Your investments are exposed to equity markets risk.	
Your investments may be subject to significant price movements due to the impact of economic, political, market, and issuer-specific factors.	
Refer to Section 7.2 of the Fund Summary for further information on market risk of the Underlying Sub-Fund.	
Liquidity Risks	
Your investments are exposed to liquidity risks of the underlying investments.	
Under exceptional market conditions the manager may be forced to sell assets of the fund at a discount in order to meet continued redemption requests.	
The Fund is not listed, and you can realize your units only on Dealing Days.	
There is no secondary market for the Fund. All redemption requests should be submitted to HSBC Life.	
Your realization request may be deferred or suspended.	
Redemptions of shares may be deferred when more than 10% of the value of the Fund's shares are redeemed or exchanged on any one Dealing Day. Your right to realize units may also be temporarily suspended under certain circumstances as described in the Fund Summary.	
Refer to Section 7.1 of the Fund Summary for information on liquidity risks of the ILP Sub-Fund and Section 9 of the Fund Summary for further information on Suspension of Dealings of the ILP Sub-Fund.	
Product-Specific Risks	
You are exposed to risk associated with the biotechnology sectors.	
The Fund tends to invest in the biotechnology sectors. These sectors may present greater risk and higher volatility than investment in a broader range of securities covering different economic sectors and tend to be subject to greater government regulation, which could have an adverse impact on the Fund's performance.	
Your investments are exposed to concentration risk.	
Refer to Section 7.2 of the Fund Summary for further information on specific risks of the Underlying Sub-Fund.	

The Fund invests primarily in a single sector, market or region, and as a result is subject to higher concentration risk and potentially greater volatility compared to funds following a more diversified policy.

Your investments exposed to risks associated with small to mid-sized companies.

The Fund will invest in small to mid-sized companies, which tend to have less liquidity and be more sensitive to changes in economic conditions and interest rates than larger, more recognized companies. As a result, the stock prices of small to mid-sized companies tend to fluctuate up and down more than those of larger companies.

Your investments are exposed to growth stocks risk.

Growth stocks may be more expensive, relative to their earnings, than the market in general and their price may be more sensitive to market sentiment, especially upon publication of quarterly financial results.

FEES AND CHARGES

WHAT ARE THE FEES AND CHARGES OF THIS INVESTMENT?

Payable directly by you as a percentage of your investment amount:

Premium Charge*	Currently Nil
Surrender Penalty*	Surrender penalty may apply. You should also refer to the Product Summary for information on the surrender penalty, if applicable.
Switching Fee*	Currently Nil

Payable by the ILP Sub-Fund from asset value of the portfolio:

Management Fee	1.00% p.a.
Annual Maintenance & Servicing Charges	Up to 0.50% p.a.
Others	Annual Custodian Fee: 0.01% to 0.14% p.a. Annual Admin Fee: Max. 0.20% p.a. plus additional amount per investor holding over one-year period.

* HSBC Life reserves the right to review and amend the fees and charges by giving you at least thirty (30) days' advance notice.

Refer to Section 8 of the Fund Summary and Section 5 of the Product Summary for further information on fees, charges and Surrender Penalty (if applicable).

VALUATIONS AND EXITING FROM THIS INVESTMENT

HOW OFTEN ARE VALUATIONS AVAILABLE?

Daily valuations are available on Dealing Days. The indicative NAV and actual NAV per share of each Fund and Share Class may be obtained from the Singapore representative's website (www.franklintempleton.com.sg) one Singapore Business Day after the relevant Dealing Day.

HOW CAN YOU EXIT FROM THIS INVESTMENT AND WHAT ARE THE RISKS AND COSTS IN DOING SO?

You can exit or partially exit the ILP Sub-Fund at any time by informing HSBC Insurance (Singapore) Pte. Limited ("**HSBC Life**"), either directly or through your Financial Consultant from whom you purchased the ILP Sub-Fund. If your application reaches our correspondence address before 3.30pm on a business day, it will be processed on the same business day. If your application is received after 3:30pm, it will be processed on the next business day. The units withdrawn will be realised at the unit price of the ILP Sub-Fund on the valuation date immediately following the date we accept your written application. The withdrawal proceeds will usually be paid out within 6 business days from the day we process your valid application to exit or partially exit the ILP Sub-Fund.

The following is an illustration of the withdrawal amount** that you will receive from the ILP Sub-Fund based on withdrawal of 1,000 units, and unit price of \$1.50 assuming the policy is surrendered in the first year with surrender penalty charge of 70% on the account value.

Refer to Section 13 of the Product Summary for more information on valuation, and Sections 7 and 8 of the Product Summary for more information on withdrawal and switching.

<p>$(1,000 \times \\$1.50) - 70\% (1,000 \times \\$1.50) = \\$450$</p> <p>Gross withdrawal amount - surrender penalty charge = Net withdrawal amount</p> <p>** You should also refer to the Product Summary for information on any surrender penalty that may be applicable.</p> <p>If you decide to terminate the Investment-Linked Policy within the free-look period of receiving your Investment-Linked Policy, HSBC Life will refund the initial premium you paid without interest, without incurring the fees and charges as stated above, less any medical and/or underwriting expenses incurred in accepting your application; and a sum to account for market fluctuation in respect of your units as determined by HSBC Life. Please note that no top-up, fund switching, partial withdrawal or surrender is allowed during the free-look period.</p>	
CONTACT INFORMATION	
<p>HOW DO YOU CONTACT US?</p> <p>Please contact your Financial Consultant or call Customer Service Hotline at (65) 6225 6111, Mondays to Fridays, 9am to 5pm.</p>	
GLOSSARY	
<p>“Dealing Day” means each day which is both a Valuation Day and a Singapore Business Day, or otherwise as the Directors may from time to time determine.</p> <p>“NAV” means Net Asset Value.</p> <p>“Singapore Business Day” means a day (except Saturdays, Sundays and public holidays) on which commercial banks are open for business in Singapore.</p> <p>“UCITS” means an undertaking for collective investment in transfer securities.</p> <p>“Valuation Day” means any day on which the New York Stock Exchange (NYSE) is open or any full day on which banks in Luxembourg are open for normal business (other than during a suspension of normal dealing).</p>	